Clinical Trial Update: A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating SI-B001 in combination with docetaxel for adenocarcinoma of the lung and squamous cell carcinoma of the lung; currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SI-B001

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING